Carlo Zanotti

Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million.

Miltenyi Biotec GmbH provides biotechnology products and services. The firm products include MACS sample preparation, MACS cell separation, MACS flow cytometry, MACS cell culture and stimulation and MACS molecular; research areas include immunology, stem cell research, neuroscience, and cancer research. Its clinical applications include clinical development, CliniMACS system, MACS GMP products, CryoMACS freezing products, TheraSorb, graft engineering, immunotherapy, tissue regeneration and freezing products. The company was founded by Stefan Miltenyi in 1989 and is headquartered in Teterow, Germany.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Biocross SL designs and develops diagnostic products for neurodegenerative diseases. Its products include multiparametric blood tests and biomarkers for identifying amytrophic lateral sclerosis, Parkinson's disease, and Alheimer's. The company was founded on January 26, 2005 and is headquartered in Boecillo, Spain.